Latest news with #Schrödinger
Globe and Mail
a day ago
- Business
- Globe and Mail
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger, Inc. (Nasdaq: SDGR) today reported that on August 15, 2025, the company granted restricted stock units (RSUs) with respect to 1,875 shares of the company's common stock to two newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The RSUs vest over four years, with 25 percent of such RSUs vesting when such employee completes 12 months of continuous service measured from the vesting commencement date, and the balance of the RSUs vesting in a series of successive equal yearly installments of 1/4 of the original number of RSUs upon each such employee's completion of each additional year of service over the three-year period following the first anniversary of the vesting commencement date. The inducement grants are subject to the terms and conditions of award agreements covering the grants and the company's 2021 Inducement Equity Incentive Plan. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs. Founded in 1990, Schrödinger has approximately 800 employees operating from 15 locations globally. To learn more, visit follow us on LinkedIn and Instagram, or visit our blog,
AllAfrica
2 days ago
- Science
- AllAfrica
US testing quantum navigation aboard secretive military space plane
A US military space plane, the X-37B orbital test vehicle, is due to embark on its eighth flight into space on August 21, 2025. Much of what the X-37B does in space is secret. But it serves partly as a platform for cutting-edge experiments. One of these experiments is a potential alternative to GPS that makes use of quantum science as a tool for navigation: a quantum inertial sensor. Satellite-based systems like GPS are ubiquitous in our daily lives, from smartphone maps to aviation and logistics. But GPS isn't available everywhere. This technology could revolutionise how spacecraft, airplanes, ships and submarines navigate in environments where GPS is unavailable or compromised. In space, especially beyond Earth's orbit, GPS signals become unreliable or simply vanish. The same applies underwater, where submarines cannot access GPS at all. And even on Earth, GPS signals can be jammed (blocked), spoofed (making a GPS receiver think it is in a different location) or disabled – for instance, during a conflict. This makes navigation without GPS a critical challenge. In such scenarios, having navigation systems that function independently of any external signals becomes essential. Traditional inertial navigation systems (INS), which use accelerometers and gyroscopes to measure a vehicle's acceleration and rotation, do provide independent navigation, as they can estimate position by tracking how the vehicle moves over time. Think of sitting in a car with your eyes closed: you can still feel turns, stops and accelerations, which your brain integrates to guess where you are over time. Eventually, though, without visual cues, small errors will accumulate and you will entirely lose your positioning. The same goes for classical inertial navigation systems: as small measurement errors accumulate, they gradually drift off course and need corrections from GPS or other external signals. If you think of quantum physics, what may come to your mind is a strange world where particles behave like waves and Schrödinger's cat is both dead and alive. These thought experiments genuinely describe how tiny particles like atoms behave. At very low temperatures, atoms obey the rules of quantum mechanics: they behave like waves and can exist in multiple states simultaneously – two properties that lie at the heart of quantum inertial sensors. The quantum inertial sensor aboard the X‑37B uses a technique called atom interferometry, where atoms are cooled to the temperature of near absolute zero, so they behave like waves. Using fine-tuned lasers, each atom is split into what's called a superposition state, similar to Schrödinger's cat, so that it simultaneously travels along two paths, which are then recombined. Since the atom behaves like a wave in quantum mechanics, these two paths interfere with each other, creating a pattern similar to overlapping ripples on water. Encoded in this pattern is detailed information about how the atom's environment has affected its journey. In particular, the tiniest shifts in motion, like sensor rotations or accelerations, leave detectable marks on these atomic 'waves.' Compared to classical inertial navigation systems, quantum sensors offer orders of magnitude greater sensitivity. Because atoms are identical and do not change, unlike mechanical components or electronics, they are far less prone to drift or bias. The result is long-duration and high-accuracy navigation without the need for external references. The upcoming X‑37B mission will be the first time this level of quantum inertial navigation is tested in space. Previous missions, such as NASA's Cold Atom Laboratory and German Space Agency's MAIUS-1, have flown atom interferometers in orbit or suborbital flights and successfully demonstrated the physics behind atom interferometry in space, though not specifically for navigation purposes. By contrast, the X‑37B experiment is designed as a compact, high-performance, resilient inertial navigation unit for real-world, long-duration missions. It moves atom interferometry out of the realms of pure science and into a practical application for aerospace. This is a big leap. This has important implications for both military and civilian spaceflight. For the US Space Force, it represents a step towards greater operational resilience, particularly in scenarios where GPS might be denied. For future space exploration, such as to the Moon, Mars or even deep space, where autonomy is key, a quantum navigation system could serve not only as a reliable backup but even as a primary system when signals from Earth are unavailable. Quantum navigation is just one part of the current, broader wave of quantum technologies moving from lab research into real-world applications. While quantum computing and quantum communication often steal headlines, systems like quantum clocks and quantum sensors are likely to be the first to see widespread use. Countries including the US, China and the UK are investing heavily in quantum inertial sensing, with recent airborne and submarine tests showing strong promise. In 2024, Boeing and AOSense conducted the world's first in-flight quantum inertial navigation test aboard a crewed aircraft. This demonstrated continuous GPS-free navigation for approximately four hours. That same year, the UK conducted its first publicly acknowledged quantum navigation flight test on a commercial aircraft. This summer, the X‑37B mission will bring these advances into space. Because of its military nature, the test could remain quiet and unpublicized. But if it succeeds, it could be remembered as the moment space navigation took a quantum leap forward. Samuel Lellouch is assistant professor in digital twinning, School of Physics and Astronomy, University of Birmingham This article is republished from The Conversation under a Creative Commons license. Read the original article.
Yahoo
2 days ago
- Business
- Yahoo
Schrödinger Announces Discontinuation of SGR-2921 Program
NEW YORK, August 14, 2025--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the discontinuation of the clinical development program for SGR-2921, its CDC7 inhibitor, which was being evaluated in a Phase 1 dose-escalation study in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. Despite early evidence of monotherapy activity observed in the Phase 1 study, based on the profile observed to date, including two emergent events where SGR-2921 was considered to have contributed to two deaths in patients with AML, Schrödinger believes the path to development as a combination therapy would be difficult to pursue. The Phase 1 study was supported by preclinical data which had demonstrated that CDC7 inhibition resulted in monotherapy and combination anti-leukemic responses in patient-derived AML models, suggesting that SGR-2921 could ultimately be used in combination with standard of care agents. "Patient safety is our first priority, and in light of two treatment-related deaths in the Phase 1 dose-escalation study, we have made the decision to discontinue further development of SGR-2921. While disappointing given the early clinical activity observed, we believe this is the right decision for patients," stated Margaret Dugan, M.D., chief medical officer at Schrödinger. "We had hoped to advance this investigational agent for acute myeloid leukemia as relapse rates are high, the disease progresses rapidly and there are limited therapies available. We are very grateful to the investigators, patients and families who have participated in this clinical study." About SchrödingerSchrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs. Founded in 1990, Schrödinger has approximately 800 employees operating from 15 locations globally. To learn more, visit follow us on LinkedIn and Instagram, or visit our blog, Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to the benefits of its computational platform. Statements including words such as "aim," "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "goal," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," "would" and statements in the future tense are forward-looking statements. These forward-looking statements reflect Schrödinger's current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and important factors that are beyond Schrödinger's control, including the uncertainties inherent in drug development, such as the conduct of research activities and the timing of and its ability to initiate and complete preclinical studies and clinical trials, whether results from preclinical and early clinical studies will be predictive of the results of later preclinical studies and clinical trials, whether initial data from clinical results will be predictive of the final results of the clinical trials, uncertainties associated with the regulatory review of clinical trials, and the ability to retain and hire key personnel and other risks detailed under the caption "Risk Factors" and elsewhere in the company's Securities and Exchange Commission filings and reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the Securities and Exchange Commission on August 6, 2025, as well as future filings and reports by the company. Any forward-looking statements contained in this press release speak only as of the date hereof. Except as required by law, Schrödinger undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, changes in expectations or otherwise. View source version on Contacts Jaren Madden (Investors and Media) 617-286-6264 Matthew Luchini (Investors) 917-719-0636 Allie Nicodemo (Media) 617-356-2325
Yahoo
2 days ago
- Business
- Yahoo
Schrödinger ends development of blood cancer drug after patient deaths
Schrödinger is discontinuing the development of its blood cancer CDC7 inhibitor after two patient deaths. In a Phase I trial (NCT05961839), SGR-2921 had originally shown activity as a monotherapy; however, the therapy was considered to have contributed to two deaths in patients with relapsed/refractory acute myeloid leukaemia (r/r AML). The trial also enrolled patients with high-risk myelodysplastic syndromes. While these deaths were in patients treated with the drug as a monotherapy, Schrödinger also believes that the path to development as a combination therapy, the original intention, would be difficult to pursue. Schrödinger CMO Dr Margaret Dugan said: 'Patient safety is our first priority, and in light of two treatment-related deaths in the Phase I dose-escalation study, we have made the decision to discontinue further development of SGR-2921. "While disappointing given the early clinical activity observed, we believe this is the right decision for patients. We had hoped to advance this investigational agent for AML as relapse rates are high, the disease progresses rapidly, and there are limited therapies available.' The company's stock opened 12.19% down, from a $19.84 close on 13 August to a $17.42 open on 14 August, shortly after the termination was confirmed. Unmet needs in AML remain There are several unmet needs in AML, especially in patients who experience relapse or do not achieve remission after initial treatment. Current therapeutic options are even more limited for AML patients with relapses. In July 2025, Sellas Life Sciences' CDK9 inhibitor SLS009 (tambiciclib), being used as a triple combination therapy, saw a mean overall response rate (ORR) of 33%, exceeding the threshold of 20%. ORR was the Phase Ia/II trial's primary endpoint. There are several therapies approved r/r AML, including Astella's Xospata (gilteritinib), Agios Pharmaceuticals' Tibsovo (ivosidenib) and Pfizer's Mylotarg (gemtuzumab ozogamicin). However, all of these are for particular mutations of AML. AbbVie's Venclexta (venetoclax) and hypomethylating agent (HMA) combinations are prescribed off-label in this patient population. According to GlobalData, the AML market is set to reach $3.68bn in 2032, across the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China). GlobalData is the parent company of Clinical Trials Arena. "Schrödinger ends development of blood cancer drug after patient deaths" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Reuters
2 days ago
- Business
- Reuters
Schrödinger stops development of blood cancer therapy after two patient deaths
Aug 14 (Reuters) - Schrödinger (SDGR.O), opens new tab said on Thursday it has stopped the development of an experimental drug after the death of two patients with a type of blood cancer in an early-stage trial, sending its shares down nearly 17% before the bell. The company was testing the therapy, SGR-2921, in patients with high-risk myelodysplastic syndromes, a group of blood cancers in which the bone marrow doesn't produce enough healthy blood cells, and its more serious form - acute myeloid leukemia. The drug was considered to have contributed to the deaths of two AML patients in the trial, the company said. "While disappointing given the early clinical activity observed, we believe this is the right decision for patients," Chief Medical Officer Margaret Dugan said. In pre-clinical trial, the therapy showed responses against the cancer, which suggested SGR-2921 could ultimately be used in combination with standard of care treatments, the company said. The experimental drug was designed to work by blocking CDC7, a protein that helps cancer cells repair DNA damage during replication. By inhibiting this protein, the drug causes cancer cells to accumulate fatal levels of DNA damage.
